DISC MEDICINE INC (IRON) Fundamental Analysis & Valuation

NASDAQ:IRON • US2546041011

Current stock price

66.32 USD
-0.98 (-1.46%)
At close:
66.32 USD
0 (0%)
After Hours:

This IRON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IRON Profitability Analysis

1.1 Basic Checks

  • In the past year IRON has reported negative net income.
  • In the past year IRON has reported a negative cash flow from operations.
  • In the past 5 years IRON always reported negative net income.
  • IRON had a negative operating cash flow in each of the past 5 years.
IRON Yearly Net Income VS EBIT VS OCF VS FCFIRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • IRON has a better Return On Assets (-26.30%) than 69.83% of its industry peers.
  • IRON's Return On Equity of -28.68% is fine compared to the rest of the industry. IRON outperforms 76.60% of its industry peers.
Industry RankSector Rank
ROA -26.3%
ROE -28.68%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRON Yearly ROA, ROE, ROICIRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • IRON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRON Yearly Profit, Operating, Gross MarginsIRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

6

2. IRON Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for IRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRON Yearly Shares OutstandingIRON Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IRON Yearly Total Debt VS Total AssetsIRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 22.27 indicates that IRON is not in any danger for bankruptcy at the moment.
  • IRON has a better Altman-Z score (22.27) than 88.59% of its industry peers.
  • A Debt/Equity ratio of 0.04 indicates that IRON is not too dependend on debt financing.
  • IRON has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: IRON outperforms 42.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 22.27
ROIC/WACCN/A
WACCN/A
IRON Yearly LT Debt VS Equity VS FCFIRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • IRON has a Current Ratio of 21.94. This indicates that IRON is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of IRON (21.94) is better than 95.74% of its industry peers.
  • A Quick Ratio of 21.94 indicates that IRON has no problem at all paying its short term obligations.
  • IRON has a better Quick ratio (21.94) than 95.74% of its industry peers.
Industry RankSector Rank
Current Ratio 21.94
Quick Ratio 21.94
IRON Yearly Current Assets VS Current LiabilitesIRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

1

3. IRON Growth Analysis

3.1 Past

  • IRON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.63%.
EPS 1Y (TTM)-50.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • IRON is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.91% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.54%
EPS Next 2Y-12.97%
EPS Next 3Y0.96%
EPS Next 5Y17.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IRON Yearly Revenue VS EstimatesIRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
IRON Yearly EPS VS EstimatesIRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40

0

4. IRON Valuation Analysis

4.1 Price/Earnings Ratio

  • IRON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRON Price Earnings VS Forward Price EarningsIRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRON Per share dataIRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.97%
EPS Next 3Y0.96%

0

5. IRON Dividend Analysis

5.1 Amount

  • No dividends for IRON!.
Industry RankSector Rank
Dividend Yield 0%

IRON Fundamentals: All Metrics, Ratios and Statistics

DISC MEDICINE INC

NASDAQ:IRON (4/10/2026, 8:00:02 PM)

After market: 66.32 0 (0%)

66.32

-0.98 (-1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-05
Inst Owners96.15%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner Change-10.96%
Market Cap2.53B
Revenue(TTM)N/A
Net Income(TTM)-212.18M
Analysts86.32
Price Target102.17 (54.06%)
Short Float %14.08%
Short Ratio6.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.37%
Min EPS beat(2)-18.57%
Max EPS beat(2)7.82%
EPS beat(4)2
Avg EPS beat(4)-8.16%
Min EPS beat(4)-33.61%
Max EPS beat(4)11.71%
EPS beat(8)5
Avg EPS beat(8)-0.06%
EPS beat(12)7
Avg EPS beat(12)-3.54%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.36%
PT rev (3m)-15.77%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)2.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.99%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-47.44%
Revenue NY rev (3m)-82.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.42
P/tB 3.42
EV/EBITDA N/A
EPS(TTM)-6.01
EYN/A
EPS(NY)-7.24
Fwd EYN/A
FCF(TTM)-4.75
FCFYN/A
OCF(TTM)-4.73
OCFYN/A
SpS0
BVpS19.39
TBVpS19.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.3%
ROE -28.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 332.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.94
Quick Ratio 21.94
Altman-Z 22.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)248.25%
Cap/Depr(5y)188.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.35%
EPS Next Y-20.54%
EPS Next 2Y-12.97%
EPS Next 3Y0.96%
EPS Next 5Y17.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.86%
EBIT Next 3Y-10.68%
EBIT Next 5YN/A
FCF growth 1Y-92.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.06%
OCF growth 3YN/A
OCF growth 5YN/A

DISC MEDICINE INC / IRON Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DISC MEDICINE INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRON.


What is the valuation status of DISC MEDICINE INC (IRON) stock?

ChartMill assigns a valuation rating of 0 / 10 to DISC MEDICINE INC (IRON). This can be considered as Overvalued.


How profitable is DISC MEDICINE INC (IRON) stock?

DISC MEDICINE INC (IRON) has a profitability rating of 1 / 10.


What is the earnings growth outlook for DISC MEDICINE INC?

The Earnings per Share (EPS) of DISC MEDICINE INC (IRON) is expected to decline by -20.54% in the next year.